Racotumomab in Non-Small Cell Lung Cancer as Maintenance and Second-Line Treatment.
Haslen Hassiul Cáceres-LaverniaElia Nenínger-VinagerasLeslie M Varona-RodríguezYoli A Olivares-RomeroIrlis Sánchez-RojasZaima Mazorra-HerreraDenenke Basanta-BergollaDayanis Duvergel-CalderínBoris L Torres-CuevasConcepción Castillo-CarrilloPublished in: MEDICC review (2021)
Racotumomab in routine clinical practice prolonged overall survival in patients with non-small cell lung cancer treated in switch maintenance, and in stage IV patients who received the treatment as second-line therapy. The vaccine was well tolerated.